A BILL 
To amend the Controlled Substances Act to require the At-
torney General to make procurement quotas for opioid 
analgesics publicly available, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Opioid Quota Open-
4
ness, Transparency, and Awareness Act of 2021’’ or the 
5
‘‘Opioid QuOTA Act of 2021’’. 
6
16:32 Jan 10, 2022
H6150
2 
•HR 6150 IH
SEC. 2. PUBLIC REPORTING OF PROCUREMENT QUOTAS 
1
FOR OPIOID ANALGESICS. 
2
(a) IN GENERAL.—Section 306 of the Controlled 
3
Substances Act (21 U.S.C. 826) is amended by adding at 
4
the end the following: 
5
‘‘(j)(1) In this subsection, the term ‘opioid procure-
6
ment quota’ means a quota established by the Attorney 
7
General for the quantity of opioid analgesics that a reg-
8
istered manufacturer may procure for purposes of manu-
9
facturing dosage forms or other substances. 
10
‘‘(2) The Attorney General shall make publicly avail-
11
able, including through the website of the Drug Enforce-
12
ment Administration— 
13
‘‘(A) the quantity of the opioid procurement 
14
quota for each registered manufacturer for each 
15
year; 
16
‘‘(B) the quantity of opioid analgesics procured 
17
by each registered manufacturer for each year; and 
18
‘‘(C) except as provided under paragraph (3)— 
19
‘‘(i) a copy of the form or other applica-
20
tion, including any attachments or exhibits, 
21
submitted by each registered manufacturer re-
22
questing an opioid procurement quota; and 
23
‘‘(ii) a copy of each year-end or annual re-
24
port relating to the procurement or use of 
25
opioid analgesics submitted to the Attorney 
26
16:32 Jan 10, 2022
H6150
3 
•HR 6150 IH
General by a registered manufacturer to whom 
1
the Attorney General has issued an opioid pro-
2
curement quota. 
3
‘‘(3)(A) Upon request by a registered manufacturer, 
4
the Attorney General may redact information identified in 
5
clause (i) or (ii) of paragraph (2)(C) from the publication 
6
required under paragraph (2) if the Attorney General de-
7
termines that public disclosure of that information is likely 
8
to cause substantial harm to the competitive position of 
9
the registered manufacturer. For purposes of a determina-
10
tion under this subparagraph, adverse publicity or embar-
11
rassment shall not constitute competitive harm. 
12
‘‘(B) A determination of the Attorney General under 
13
subparagraph (A) shall be subject to judicial review in ac-
14
cordance with chapter 7 of title 5, United States Code. 
15
‘‘(C) The Attorney General shall annually publish a 
16
report on the website of the Department of Justice con-
17
taining an accounting of each declination determination 
18
made under subparagraph (A), including the reason for 
19
the declination, during the time period covered by the re-
20
port.’’. 
21
(b) GAO REPORT.—The Comptroller General of the 
22
United States shall submit to Congress a report that, for 
23
the 1-year period beginning on the date of enactment of 
24
this Act— 
25
16:32 Jan 10, 2022
H6150
4 
•HR 6150 IH
(1) details— 
1
(A) the number of instances in which a 
2
registered manufacturer made a request de-
3
scribed in section 306(j)(3) of the Controlled 
4
Substances Act, as added by subsection (a), 
5
with respect to a document or information; and 
6
(B) the number of instances in which the 
7
Attorney General redacted information de-
8
scribed in clause (i) or (ii) of subsection 
9
(j)(2)(C) of the Controlled Substances Act, as 
10
added by subsection (a), from the publication 
11
required under such subsection (j)(2); and 
12
(2) evaluates, in a fair, compliant, and trans-
13
parent manner, the extent of the independent eval-
14
uation conducted by the Attorney General of re-
15
quests described in section 306(j)(3) of the Con-
16
trolled Substances Act, as added by subsection (a). 
17
Æ 
16:32 Jan 10, 2022
H6150
